Skip to content

Validation of a Molecular Prognostic Test for Eye Melanoma

Validation of a Molecular Test for Predicting Metastasis in Patients With Uveal Melanoma

Status
Withdrawn
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00406120
Enrollment
0
Registered
2006-12-04
Start date
2007-05-31
Completion date
2010-05-31
Last updated
2018-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Choroid Neoplasms, Iris Neoplasms, Uveal Neoplasms

Keywords

eye, uvea, iris, choroid, ciliary body, melanoma, iris melanoma, choroidal melanoma, ciliary body melanoma, uveal melanoma, posterior uveal melanoma, prognosis, metastasis, genetic testing, molecular testing, gene expression profiling

Brief summary

Up to half of patients with ocular melanoma (also called iris, choroidal or uveal melanoma) develop metastasis. We have found that certain molecular features of the eye tumor can be detected by gene expression profiling and accurately predict which patients will develop metastasis. This molecular test could eventually allow high risk patients to receive preventative therapy to delay or prevent the development of metastasis. The goal of this study is to prospectively validate the predictive accuracy of the gene expression-based molecular test and compare it to monosomy 3, the most common but potentially less accurate molecular marker for metastasis in ocular melanoma.

Detailed description

We have discovered a gene expression profile derived from primary uveal melanomas that accurately predicts which patients will develop metastasis. Tumors with a class 1 gene expression signature have a very low risk, and those with a class 2 signature have a high risk of metastasis. The molecular test was initially performed on tissue obtained from enucleated eyes using commercial microarray platforms. We are now able to perform the molecular test on fine needle biopsy specimens, and we have developed a customized test that has greater dynamic range and sensitivity than commercial microarray platforms. The goal of this study is to validate the prognostic accuracy of the customized platform by performing the molecular test on primary uveal melanomas obtained from enucleation, local tumor resection or fine needle biopsy. Each sample will be diagnosed as either class 1, class 2 or indeterminate. Outcomes will be collected and the ability of the molecular diagnosis to predict metastasis will be evaluated at regular intervals.

Interventions

Sponsors

Washington University School of Medicine
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* clinical diagnosis of melanoma of the iris, ciliary body and/or choroid * treatment to include enucleation, radiotherapy or local tumor resection

Exclusion criteria

* evidence of marked tumor necrosis

Design outcomes

Primary

MeasureTime frame
Presentation of Primary Tumor to Metastasis60 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026